US2017362275A1PendingUtilityA1

Growth Hormone Releasing Peptides

65
Assignee: IPSEN PHARMA SASPriority: Aug 9, 2002Filed: Aug 29, 2017Published: Dec 21, 2017
Est. expiryAug 9, 2022(expired)· nominal 20-yr term from priority
Inventors:Zheng Xin Dong
A61P 9/00A61P 5/06A61P 3/10A61P 9/10A61P 3/06A61P 43/00A61P 5/08A61P 39/00A61P 9/04A61P 9/12A61P 5/02A61P 3/04A61P 27/02A61P 35/00A61P 3/00A61P 29/00A61P 21/00A61P 1/16A61P 15/00A61P 19/10A61P 15/08A61P 19/02C07K 7/02C07K 5/0205C07K 5/1024C07K 7/06C07K 5/06034C07K 14/60A61K 38/00C07K 5/1016A61K 38/40C07K 5/08C07K 5/00C07K 5/06
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R 1 -A 1 -A 2 -A 3 -A 4 -A 5 -R 2    (I) wherein: A 1 is Aib, Apc or Inp; A 2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A 3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A 4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A 5 is Apc, Dab, Dap, Lys, Orn, or deleted; R 1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R 2 is OH or NH 2 ; and pharmaceutical compositions and methods of use thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound according to formula (I):
   R 1 -A 1 -A 2 -A 3 -A 4 -A 5 -R 2    (I)
   
       or a pharmaceutically acceptable salt thereof, wherein:
 A 1  is Aib, Apc or Inp; 
 A 2  is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; 
 A 3  is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; 
 A 4  is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); 
 A 5  is Apc, Dab, Dap, Lys, Orn, or deleted; 
 R 1  is hydrogen, (C 1-6 )alkyl, (C 5-14 )aryl, (C 1-6 )alkyl(C 5-14 )aryl, (C 3-8 )cycloakyl, or (C 2-10 )acyl; and 
 R 2  is OH or NH 2 ; 
 
       provided that:
 when A 5  is Dab, Dap, Lys, or Orn, then:
 A 2  is D-Bip, D-Bpa, D-Dip or D-Bal; or 
 A 3  is D-Bip, D-Bpa, D-Dip or D-Bal; or 
 A 4  is 2Thi, 3Thi, Taz, 2Fua, 2Pal, 3Pal, 4Pal, Orn, Thr(Bzl), or Pff; 
 
 when A 5  is deleted, then:
 A 3  is D-Bip, D-Bpa, or D-Dip; or 
 A 4  is 2Fua, Pff, Taz, or Thr(Bzl); or 
 A 1  is Apc and—
 A 2  is D-Bip, D-Bpa, D-Dip or D-Bal; or 
 A 3  is D-Bip, D-Bpa, D-Dip or D-Bal; or 
 A 4  is 2Thi, 3Thi, Orn, 2Pal, 3Pal, or 4Pal; 
 
 
 
     
     
         2 . A compound according to  claim 1 , wherein:
 A 1  is Aib, Apc or H-Inp;   A 2  is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp;   A 3  is D-Bal, D-Bpa, D-Dip, D-1Nal, D-2Nal, or D-Trp;   A 4  is Orn, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl); and   A 5  is Apc, Lys, or deleted;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A compound according to  claim 2 , wherein:
 A 1  is Apc or H-Inp;   A 2  is D-Bal, D-Bip, D-1Nal, or D-2Nal;   A 3  is D-Bal, D-1Nal, D-2Nal, or D-Trp;   A 4  is 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl); and   
       or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A compound according to  claim 1 , wherein said compound is according to the formula:
 H-Inp-D-1Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Orn-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Dip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bpa-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Bpa-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Pal-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Pal-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-Dip-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Dip-Phe-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Bal-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-Trp-D-2Nal(ψ)-Pim;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp(ψ)-Pim;   H-Inp-D-1Nal-D-Trp(ψ)-Pim;   H-Inp-D-Bal-D-Trp(ψ)-Pim;   H-Aib-D-Ser(Bzl)-D-Trp(ψ)-Pim;   H-Inp-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Pal-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Pal-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-NH 2 ;   H-Apc-D-1Nal-D-Trp-4Pal-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-4Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-NH 2 ;   H-Apc-D-Bal-D-Bal-2 Pal-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-NH 2 ;   H-Apc-D-Bal-D-Bal-3 Pal-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-NH 2 ;   H-Apc-D-Bal-D-Bal-4 Pal-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-NH 2 ;   H-Apc-D-Bal-D-Trp-2 Pal-NH 2 ;   H-Apc-D-Bal-D-Trp-3 Pal-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-4Pal-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Fua-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Fua-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Pff-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Pff-NH 2 ;   H-Inp-D-1Nal-D-Bal-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Taz-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Taz-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Fua-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-Bal-D-Bal-2Fua-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-2Fua-NH 2 ;   H-Inp-D-Bal-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Pff-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Pff-NH 2 ;   H-Inp-D-Bal-D-Bal-Phe-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Taz-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-NH 2 ;   H-Inp-D-Bal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-NH 2 ;   H-Inp-D-Bip-D-Bal-2Fua-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-2Fua-NH 2 ;   H-Inp-D-Bip-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-Pff-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-Pff-NH 2 ; or   H-Inp-D-Bip-D-Bal-Taz-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-Taz-NH 2 ;   H-Inp-D-Bip-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-2Fua-NH 2 ;   H-Inp-D-Bip-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Pff-NH 2 ;   H-Inp-D-Bip-D-Trp-Taz-Lys-NH 2 ; or   H-Inp-D-Bip-D-Trp-Taz-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         5 . A compound according to  claim 4 , wherein said compound is according to the formula:
 H-Inp-D-1Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Orn-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Dip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bpa-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Bpa-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-2Nal-D-Dip-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-Trp-D-2Nal(ψ)-Pim;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp(ψ)-Pim;   H-Inp-D-1Nal-D-Trp(ψ)-Pim;   H-Inp-D-Bal-D-Trp(ψ)-Pim;   H-Aib-D-Ser(Bzl)-D-Trp(ψ)-Pim;   H-Inp-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Phe-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-2Fua-Lys-NH 2 ;   H-Inp-D-Bal-D-Bal-Pff-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-Lys-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Taz-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Fua-Lys-NH 2 ;   H-Inp-D-1Nal-D-Bal-Pff-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-3Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-2Fua-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-2Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-3Thi-Lys-NH 2 ;   H-Inp-D-Bip-D-Bal-2Fua-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-Apc-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-NH 2 ;   H-Inp-D-Bal-D-Trp-2Fua-NH 2 ;   H-Inp-D-Bal-D-Trp-Pff-NH 2 ;   H-Apc-D-Bal-D-Trp-3Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-2Fua-NH 2 ;   H-Apc-D-Bal-D-Trp-Pff-NH 2 ;   H-Apc-D-Bal-D-Trp-4Pal-NH 2 ;   H-Apc-D-Bal-D-Trp-3Pal-NH 2 ;   H-Apc-D-Bal-D-Trp-2Pal-NH 2 ;   H-Inp-D-Bal-D-Bal-Taz-NH 2 ;   H-Inp-D-Bal-D-Bal-2Fua-NH 2 ;   H-Inp-D-Bal-D-Bal-Pff-NH 2 ;   H-Apc-D-Bal-D-Bal-Phe-NH 2 ;   H-Apc-D-Bal-D-Bal-2Thi-NH 2 ;   H-Apc-D-Bal-D-Bal-3Thi-NH 2 ;   H-Apc-D-Bal-D-Bal-Taz-NH 2 ;   H-Apc-D-Bal-D-Bal-2Fua-NH 2 ;   H-Apc-D-Bal-D-Bal-Pff-NH 2 ;   H-Apc-D-Bal-D-Bal-4Pal-NH 2 ;   H-Apc-D-Bal-D-Bal-3Pal-NH 2 ;   H-Apc-D-Bal-D-Bal-2Pal-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Fua-NH 2 ;   H-Inp-D-1Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-1Nal-D-Bal-Taz-NH 2 ;   H-Inp-D-1Nal-D-Bal-2Fua-NH 2 ;   H-Inp-D-1Nal-D-Bal-Pff-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Fua-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Thi-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Fua-NH 2 ;   H-Apc-D-1Nal-D-Trp-Pff-NH 2 ;   H-Apc-D-1Nal-D-Trp-4Pal-NH 2 ;   H-Apc-D-1Nal-D-Trp-3Pal-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Fua-NH 2 ;   H-Apc-D-2Nal-D-Trp-Pff-NH 2 ;   H-Apc-D-2Nal-D-Trp-4Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-3Pal-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Pal-NH 2 ;   H-Inp-D-Bip-D-Trp-Taz-NH 2 ;   H-Inp-D-Bip-D-Trp-2Fua-NH 2 ;   H-Inp-D-Bip-D-Trp-Pff-NH 2 ;   H-Inp-D-Bip-D-Bal-Taz-NH 2 ;   H-Inp-D-Bip-D-Bal-2Fua-NH 2 ; or   H-Inp-D-Bip-D-Bal-Pff-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         6 . A compound according to  claim 5 , wherein said compound is according to the formula:
 H-Inp-D-1Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Orn-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Dip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bpa-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Bpa-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp(ψ)-Pim;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-2Nal-D-Trp(ψ)-Pim;   H-Inp-D-Trp-D-2Nal(ψ)-Pim;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-2Nal-D-Dip-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp(ψ)-Pim;   H-Apc-D-Bal-D-Trp-Phe-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-NH 2 ; or   H-Aib-D-Ser(Bzl)-D-Trp(ψ)-Pim;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         7 . A compound according to  claim 6 , wherein said compound is according to the formula:
 H-Inp-D-1Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-Lys-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Thr(Bzl)-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-1Nal-Phe-Lys-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-Taz-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Apc-NH 2 ; or   H-Apc-D-Bal-D-Trp-Taz-Apc-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         8 . A compound according to  claim 7 , wherein said compound is according to the formula:
 H-Inp-D-1Nal-D-Trp-3Pal-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-Bal-D-2Nal-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-NH 2 ;   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Inp-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Apc-NH 2 ; or   
       or a pharmaceutically acceptable salt thereof. 
     
     
         9 . A compound according to  claim 8 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-1Nal-D-Trp-Phe-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-2Nal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Phe-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ; or   H-Apc-D-2Nal-D-Trp-2Thi-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         10 . A compound according to  claim 9 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A compound according to  claim 9 , wherein said compound is according to the formula:
 H-Inp-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-Bal-D-Trp-Taz-Lys-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-Apc-NH 2 ; or   
       or a pharmaceutically acceptable salt thereof. 
     
     
         12 . A compound according to  claim 6 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-Orn-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-DDip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-Bpa-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Bpa-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-2Nal-DDip-Phe-NH 2 ;   H-Inp-D-Trp-D-2Nal(ψ)-Pim   H-Inp-D-2Nal-D-Trp(ψ)-Pim   H-Inp-D-1Na-D-Trp(ψ)-Pim   H-Inp-D-Bal-D-Trp(ψ)-Pim   H-Aib-DSer(Bzl)-D-Trp(ψ)-Pim   H-Inp-D-Bal-D-tryptophanol   H-Inp-D-Bal-D-tryptophyl benzyl ether   
       or a pharmaceutically acceptable salt thereof. 
     
     
         13 . A compound according to  claim 12 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-Pff-Lys-NH 2 ;   H-Inp-DDip-D-Trp-Phe-Lys-NH 2 ;   H-Inp-D-2Nal-D-Trp-Pff-NH 2 ;   H-Inp-D-1Na-D-Trp(ψ)-Pim   H-Inp-D-Bal-D-Trp(ψ)-Pim   H-Inp-D-Bal-D-tryptophanol   H-Inp-D-Bal-D-tryptophyl benzyl ether   
       or a pharmaceutically acceptable salt thereof. 
     
     
         14 . A compound according to  claim 4 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-3Pal-NH 2 ;   H-Inp-D-2Nal-D-Trp-4Pal-NH 2 ;   H-Inp-D-1Nal-D-Trp-3Pal-NH 2 ;   H-Inp-D-Bip-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Inp-D-2Nal-D-Trp-3Thi-NH 2 ;   H-Inp-D-Dip-D-Trp-Phe-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-NH 2 ;   H-Inp-D-2Nal-D-Bal-Phe-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-NH 2 ;   H-Apc-D-1Nal-D-Trp-Phe-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         15 . A compound according to  claim 14 , wherein said compound is according to the formula:
 H-Inp-D-2Nal-D-Trp-2Thi-NH 2 ;   H-Inp-D-Bal-D-Trp-Phe-NH 2 ;   H-Inp-D-1Nal-D-Trp-2Thi-NH 2 ; or   H-Apc-D-1Nal-D-Trp-Phe-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         16 . A compound according to the formula:
 H-Inp-D-1Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Inp-D-Bal-D-Trp-2Thi-Apc-NH 2 ;   H-Apc-D-1Nal-D-Trp-2Thi-Apc-NH 2 ;   H-Apc-D-Bal-D-Trp-2Thi-Apc-NH 2 ; or   H-Apc-D-1Nal-D-Trp-Phe-Lys-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         17 . A method of determining a compound's ability to bind to a GHS receptor, said method comprising the step of measuring the ability of a compound to affect binding of a compound according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1 to said receptor, to a fragment of said receptor, to a polypeptide comprising said fragment of said receptor, or to a derivative of said polypeptide. 
     
     
         18 . A method for achieving a beneficial affect in a subject in a subject in need thereof, said method comprising the step of administering to said subject an effective amount of a compound according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is effective for producing a beneficial effect in helping to treat (e.g., cure or reduce the severity) or prevent (e.g., reduce the likelihood of onset or severity) a disease or disorder. 
     
     
         19 . A method for stimulating growth hormone secretion in a subject in need of such stimulation, comprising the step of administering to a subject an effective amount of a ghrelin agonist according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least an amount sufficient to produce a detectable increase in growth hormone secretion and, preferably, is an amount sufficient to achieve a beneficial affect in a patient. 
     
     
         20 . A method according to  claim 19  wherein said stimulation of growth hormone secretion is indicated for treatment of a growth hormone deficient state, for increasing muscle mass, for increasing bone density, for sexual dysfunction in males or females, for facilitating a weight gain, for facilitating maintenance of weight, for facilitating maintenance of physical functioning, for facilitating recovery of physical function, and/or facilitating appetite increase. 
     
     
         21 . A method according to  claim 20  wherein said facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase is indicated in a patient having a disease or disorder, or under going a treatment, accompanied by weight loss. 
     
     
         22 . A method according to  claim 21  wherein said diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, AIDS wasting, cachexia, and wasting in frail elderly. 
     
     
         23 . A method according to  claim 21  wherein said treatments accompanied by weight loss include chemotherapy, radiation therapy, temporary or permanent immobilization, and dialysis. 
     
     
         24 . A method for suppressing growth hormone secretion in a subject in need of such suppression, comprising the step of administering to a subject an effective amount of a ghrelin antagonist according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least an amount sufficient to produce a detectable decrease in growth hormone secretion and, preferably, is an amount sufficient to achieve a beneficial affect in a patient. 
     
     
         25 . A method according to  claim 24  wherein said suppression of growth hormone secretion is indicated for the treatment of a disease or condition characterized by excessive growth hormone secretion, for facilitation of weight loss, for facilitation of appetite decrease, for facilitation of weight maintenance, for treating obesity, for treating diabetes, for treating complications of diabetes including retinopathy, and/or for treating cardiovascular disorders. 
     
     
         26 . A method according to  claim 25  wherein said excessive weight is a contributing factor to a disease or condition including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and cancers. 
     
     
         27 . A method according to  claim 26  wherein said facilitation of weight loss reduces the likelihood of such diseases or conditions. 
     
     
         28 . A method according to  claim 26  wherein said facilitation of weight loss comprises at least part of a treatment for such diseases or conditions. 
     
     
         29 . A method of eliciting a ghrelin agonist effect in a subject, comprising the step of administering to a subject an effective amount of a ghrelin agonist according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least an amount sufficient to produce a detectable increase in growth hormone secretion and, preferably, is an amount sufficient to achieve a beneficial affect in a patient. 
     
     
         30 . A method of eliciting a ghrelin antagonist effect in a subject, comprising the step of administering to a subject an effective amount of a ghrelin antagonist according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least an amount sufficient to produce a detectable decrease in growth hormone secretion and, preferably, is an amount sufficient to achieve a beneficial affect in a patient. 
     
     
         31 . A method of achieving a beneficial cardiovascular effect in a subject in need thereof, comprising the step of administering to a subject an effective amount of a ghrelin agonist according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, Group 2C-1 or Group 3, or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least an amount sufficient to produce a beneficial affect in said subject. 
     
     
         32 . A method according to  claim 31 , wherein said beneficial cardiovascular effect comprises inhibition of apoptosis of cardiomyocytes, cardiac endothelial cells, or vascular endothelial cells. 
     
     
         33 . A method according to  claim 31 , wherein said beneficial cardiovascular effect comprises improvement of cardiac structure or function. 
     
     
         34 . A method according to  claim 31 , wherein said beneficial cardiovascular effect comprises attenuation of the development of cardiac cachexia. 
     
     
         35 . A method according to  claim 31 , wherein said beneficial cardiovascular effect comprises a reduction in systemic vascular resistance. 
     
     
         36 . A method according to  claim 31 , wherein said beneficial cardiovascular effect comprises an increase in cardiac output. 
     
     
         37 . A method according to any one of  claims 31 - 36 , wherein said subject comprises a human. 
     
     
         38 . A method according to  claim 37 , wherein said human suffers from chronic heart failure or severe chronic heart failure. 
     
     
         39 . A compound according to  claim 11 , wherein said compound is according to the formula:
 H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         40 . A method according to any one of  claim 17 - 23 ,  29 , or  31 - 38 , wherein said ghrelin agonist is according to the formula:
 H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 ;   
       or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.